在处理和恩替卡韦的离疗效的慢性乙肝患者的现实生活中的

StephenW

Eur J Gastroenterol Hepatol. 2016 Jul 15. [Epub ahead of print]
On-treatment and off-treatment efficacy of entecavir in a real-life cohort of chronic hepatitis B patients.Park CH1, Kim HY, Lee SW, Song DS, Song MJ, Kwon JH, You CR, Jang JW, Kim CW, Choi SW, Bae SH, Choi JY, Yoon SK.
Author information

AbstractBACKGROUND AND AIMS: Entecavir (ETV) is a potent nucleoside analogue with high genetic barrier to resistance. In this study, real-life clinical experiences in the long-term use of ETV and the durability of its off-treatment effectiveness were analyzed.
MATERIALS AND METHODS: This study was based on a large real-life cohort of 2240 chronic hepatitis B patients treated with ETV between January 2006 and December 2012 using a centralized electronic data repository.
RESULTS: Among 2240 patients, 804 patients were treatment naive and underwent ETV monotherapy. Their mean treatment duration was 712±493 days, with a cumulative proportion of patients achieving HBV DNA less than 300 copies/ml in 85.8, 95.7, and 97.6% at years 1, 2, and 3, respectively. Predictors for earlier virologic response were female sex, lower HBV DNA, higher alanine transaminase, lower platelet count, and HBeAg negativity at baseline. In patients who achieved virologic response and HBeAg loss, the cumulative relapse rate was 91.3% in 2 years after the cessation of treatment. During the treatment, 34 patients developed hepatocellular carcinoma, among whom 30 patients had cirrhosis before treatment initiation. ETV treatment showed efficient virologic response as the treatment duration was extended, but off-treatment efficacy was not durable, and the antiviral treatment showed some limitation in preventing hepatocellular carcinoma among liver cirrhosis patients, implying that treatment cessation should be taken into consideration more carefully.
CONCLUSION: This study from a real-life cohort may provide data on treating chronic hepatitis B patients more close to everyday clinical practice.


PMID:27428552DOI:10.1097/MEG.0000000000000691

StephenW

欧元J Gastroenterol肝脏病。 2016年15月[提前打印EPUB]
在处理和恩替卡韦的离疗效的慢性乙肝患者的现实生活中的队列。
公园CH1，金HY，李SW，宋DS，宋MJ，权JH，你CR，张JW，金CW，崔SW，裴SH，JY崔尹SK。
作者信息
抽象
背景和目的：

恩替卡韦（ETV）是一种有效的核苷类似物具有高耐药基因屏障。在这项研究中，在长期使用ETV及其离治疗效果的耐久性现实生活中的临床经验进行了分析。
材料和方法：

这项研究是基于使用一个集中的电子数据存储库的恩替卡韦2006年1月和2012年12月间共收治2240慢性乙肝患者的大型现实生活队列。
结果：

其中2240例，804例，初治并接受ETV单药治疗。它们的平均处理时间为712±493天，与患者的累积比例在85.8，95.7实现HBV DNA小于300拷贝/ ml，和97.6％的年1，2，和3中，分别。早期病毒学应答预测因素为女性，较低的HBV DNA，较高的丙氨酸转氨酶，降低血小板计数，和HBeAg阴性基线。在谁取得病毒学应答和HBeAg消失的患者，累计复发率的治疗停止后，在2年内91.3％。治疗过程中，34例发展肝细胞癌人，其中30名患者治疗开始前患有肝硬化。 ETV治疗表明高效病毒学应答的治疗持续时间被延长，但离治疗疗效不耐用，以及抗病毒治疗的表现出某些局限性预防肝硬化患者的肝癌，这意味着停止治疗，应更仔细考虑。
结论：

这从一个真实的队列研究可能对治疗慢性乙型肝炎患者更贴近日常临床实践提供数据。

结论：
    27428552
DOI：
    10.1097 / MEG.0000000000000691